UY34008A - ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. - Google Patents

?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.

Info

Publication number
UY34008A
UY34008A UY0001034008A UY34008A UY34008A UY 34008 A UY34008 A UY 34008A UY 0001034008 A UY0001034008 A UY 0001034008A UY 34008 A UY34008 A UY 34008A UY 34008 A UY34008 A UY 34008A
Authority
UY
Uruguay
Prior art keywords
forms
prepare
processes
pharmaceutical composition
solid state
Prior art date
Application number
UY0001034008A
Other languages
English (en)
Inventor
Zheng Jane Li
Li Zhibin
Luo Laibin
Offerdahl Thomas
Kim Soojin
Bing-Shiou Yang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY34008A publication Critical patent/UY34008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a nuevas formas cristalinas de ácido (2S)?2?ter?butoxi?2?(4?(2,3?dihidropirano[4,3,2?de]quinolin?7?il)?2?metilquinolin?3?il)acético, su sal clorhidrato, nuevas formas cristalinas de la sal clorhidrato, sus métodos de preparación, sus composiciones farmacéuticas y su uso en el tratamiento de infección por virus de inmunodeficiencia humana (HIV).
UY0001034008A 2011-04-04 2012-04-09 ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. UY34008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471655P 2011-04-04 2011-04-04
US201161481908P 2011-05-03 2011-05-03

Publications (1)

Publication Number Publication Date
UY34008A true UY34008A (es) 2012-11-30

Family

ID=45992855

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034008A UY34008A (es) 2011-04-04 2012-04-09 ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.

Country Status (9)

Country Link
US (1) US20140094486A1 (es)
EP (1) EP2694160A1 (es)
JP (1) JP2014510139A (es)
AR (1) AR085856A1 (es)
AU (1) AU2012240313A1 (es)
CA (1) CA2830845A1 (es)
TW (1) TW201302761A (es)
UY (1) UY34008A (es)
WO (1) WO2012138669A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
EA201291301A1 (ru) 2010-07-02 2013-05-30 Джилид Сайэнс, Инк. Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
WO2012138670A1 (en) * 2011-04-04 2012-10-11 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
EA024952B1 (ru) 2011-04-21 2016-11-30 Джилид Сайэнс, Инк. Бензотиазолы и их применение для лечения вич-инфекции
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
RU2014115227A (ru) 2012-04-20 2015-10-27 Джилид Сайэнс, Инк. Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
WO2014055618A1 (en) * 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
CN118477088A (zh) 2017-12-07 2024-08-13 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
CN111333667B (zh) * 2020-04-14 2021-04-27 浙江工业大学 一种含硒杂环的萘酰亚胺类衍生物及其制备方法和抗病毒应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0649651B1 (en) 1993-09-28 2000-12-13 R.P. Scherer GmbH Soft gelatin capsule manufacture
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
AU2012240313A1 (en) 2013-05-02
AR085856A1 (es) 2013-10-30
CA2830845A1 (en) 2012-10-11
WO2012138669A1 (en) 2012-10-11
EP2694160A1 (en) 2014-02-12
TW201302761A (zh) 2013-01-16
US20140094486A1 (en) 2014-04-03
JP2014510139A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
CL2015001055A1 (es) Composiciones para lavado de ropa; y uso de dicha composicion.
TR201911140T4 (tr) Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
BR112014000236A2 (pt) lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
GT201400017A (es) Derivados de piridin-2 (1h) -ona como inhibidores de jak
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019